This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

DXB - Dimeriz Limited

Jump to new
so, clearly keeping a low profile.
Market cap 20mill.

up a bit today on news , 150 per cent.

AGREEMENT TO COMMERCIALISE DMX-200 IN EUROPE, CANADA, AUSTRALIA, AND NEW ZEALAND
• ADVANZ PHARMA acquires exclusive rights to register and commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis in the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand
• Dimerix to receive up to ~AU$230* million in upfront and milestone payments, plus royalties
o €6.5 million (~AU$10.8 million*) in upfront payment
o up to €132 million (~AU$219 million*) in potential milestones
o tiered royalties on net sales
• Focal Segmental Glomerulosclerosis is a rare disease that causes kidney scarring and can lead to end-stage kidney disease
• DMX-200 is in development in the global ACTION3 Phase 3 clinical trial; first analysis outcome expected to be reported on, or around, 15 March 2024
• ADVANZ PHARMA will leverage its specialty, hospital, and rare disease expertise and commercial platform to register and effectively promote the product and offer greater patient access
• Dimerix retains all rights to DMX-200 in all other territories.
.
 
Last edited:
One of the biotechs T Locantro pumped in 2020 and dropped from his list later on. Anyone who bought and held from back then is still out of the money and this has probably already shot its load from this announcement.
Don't follow Locantro anymore - his tip sheet has been disastrous for outsiders (and pbly his clients) and all he tweets on these days is his diet (meat and salt), weight loss, restaurants, netflix binges and rock concerts. There was a blip of positive weekly volume at the start of July - maybe anticipatory?

WEEKLY
 
thx, a worthy summary that saves me having to go further.
 
I like this chart. It starts with the massive price spike after DXB announced license agreements for EU, Canada and ANZ (5/10/23). Since then there's been a little selling but not too much below the open of that spike. Price has held up well indicating that there's some underlying demand to offset the short term profit sellers. Price has started to rally again and looks like going higher.

 
Staying with DXB for Feb as it continues higher in 2024 (Up 2% Jan).
DXB has potential to collect ongoing royalties from licensing agreements. That will get them more cash. Current clinical trial due to report in March. Wait March? I'm a month too early drat.
 
peter2 said:
Staying with DXB for Feb as it continues higher in 2024...DXB has potential to collect ongoing royalties from licensing agreements. That will get them more cash. Current clinical trial due to report in March. Wait March? I'm a month too early drat.
Click to expand...
should have listened to myself ... as well as you guys.

.


And presenting to Euroz Hartleys today ... ==> some interest.
 
Data collection for PH3 clinical trial is complete. Results to be reported in March.
 
Here we go again.
I've had this one on my " Deplorables " watchlist for ever , it seems .
It only takes a bit of share price lift and ...... sure enough , the buggers will be putting their grubby hands into the punters' pockets .
 
peter2 said:
How much of a discount this time?
Click to expand...
nil !!

$20 mill

The issue price of A$0.30 represents a nil discount to the Company’s last traded price before the release of this announcement, a premium of 29.2% to the 30-day VWAP (A$0.232), a premium of 14.5% to the 5-day VWAP (A$0.262) and a 52 week share price high. Euroz Hartleys acted as the sole Lead Manager of the Placement.
 
I have entered DXB as my entry for the June Competition.

With DXB at a new 52 week high and what appears to be recent brokers recomendations, along a little luck, we will see how it sits at the end of June.

bux
 
After last months dissapointing performance I have decided to give DXB a last chance for reprieve in the July stock picking Competition.

After a sharp rise DXB has dipped and consolidated a little. If I squint a bit and cross my fingers who know's, but also know it is hard to be a winner.

bux
 
• FUSO acquires exclusive rights to develop, register and commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Japan
• FUSO will be responsible for all clinical trial costs in Japan; Dimerix retains responsibility for clinical trial costs outside of Japan
• Dimerix to receive up to ¥10.5 billion (~AU$107 million) in upfront, development and sales milestone payments, plus royalties:
o ¥300 million (~AU$3.1 million) within 40 days of execution of the agreement
o ¥400 million (~AU$4.1 million) first development milestone on first clinical site initiation in Japan, anticipated Q1 2025
o up to ¥3 billion (~AU$30.6 million) in further potential development milestones
o up to ¥6.8 billion (~AU$69.4 million) in potential sales milestones
o 15-20% royalties on net sales
• ACTION clinical trial approved by the Japanese Pharmaceutical and Medical Device Agency, the Japanese regulatory agency
• Sites to open in Japan to support recruitment of ACTION clinical trial, with approximately 20 patients to be recruited to support potential approval in Japan
• FUSO is the third license deal executed for DMX-200 following the license deal with Advanz Pharma (announced October 2023) and Taiba (announced May 2024);
o Collectively the license deals provide up to ~AU$458 million in upfront payments and potential milestone payments, plus royalties on net sales
• DMX-200 is in development in the global ACTION3 Phase 3 clinical trial for the treatment of FSGS, a rare kidney disease, with approximately 1,400 patients having received treatment in Japan in 2023
• Dimerix retains all rights to DMX-200 in all territories other than those covered by the FUSO, Advanz Pharma and Taiba license agreement

 
I have Entered the DXB in the 2025 Regatta
I like Large GAP UPS as long as they don't come back to Bite Me-
 
You must log in or register to reply here.
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...